Warning: The NCBI web site requires JavaScript to function. more...
Expression and prognostic significance of lysozyme in male breast cancer.
Serra C, Vizoso F, Alonso L, Rodríguez JC, González LO, Fernández M, Lamelas ML, Sánchez LM, García-Muñiz JL, Baltasar A, Medrano J.
Breast Cancer Res. 2002;4(6):R16. Epub 2002 Aug 27.
Related citations
Lysozyme expression by breast carcinomas, correlation with clinicopathologic parameters, and prognostic significance.
Vizoso F, Plaza E, Vázquez J, Serra C, Lamelas ML, González LO, Merino AM, Méndez J.
Ann Surg Oncol. 2001 Sep;8(8):667-74.
Pepsinogen C is a new prognostic marker in primary breast cancer.
Vizoso F, Sánchez LM, Díez-Itza I, Merino AM, López-Otín C.
J Clin Oncol. 1995 Jan;13(1):54-61.
Expression and clinical significance of apolipoprotein D in male breast cancer and gynaecomastia.
Serra Díaz C, Vizoso F, Lamelas ML, Rodríguez JC, González LO, Baltasar A, Medrano J.
Br J Surg. 1999 Sep;86(9):1190-7.
Expression of pepsinogen C in gynecomastias and male breast carcinomas.
Serra Díaz C, Vizoso F, Rodríguez JC, Merino AM, González LO, Baltasar A, Pérez-Vázquez MT, Medrano J.
World J Surg. 1999 May;23(5):439-45.
LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA.
Anticancer Res. 2004 Jul-Aug;24(4):2391-400.
Comparative study of two androgen-induced markers (apolipoprotein D and pepsinogen C) in female and male breast carcinoma.
Serra C, Vizoso F, Lamelas ML, Rodríguez JC, González LO, Merino AM, Baltasar A, Pérez-Vázquez MT, Medrano J.
Int J Surg Investig. 2000;2(3):183-92.
Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray.
Dakin Haché K, Gray S, Barnes PJ, Dewar R, Younis T, Rayson D.
Breast Cancer Res Treat. 2007 Oct;105(2):169-75. Epub 2007 Feb 1.
A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.
Di Saverio S, Gutierrez J, Avisar E.
Breast Cancer Res Treat. 2008 Oct;111(3):541-7. Epub 2007 Nov 18.
BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients.
Kwiatkowska E, Teresiak M, Filas V, Karczewska A, Breborowicz D, Mackiewicz A.
Clin Cancer Res. 2003 Oct 1;9(12):4452-9.
TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.
Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, Ikdahl T, Kåresen R, Børresen-Dale AL, Jeffrey SS.
Breast Cancer Res. 2007;9(3):R30.
Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer--a retrospective study.
Vinayagam R, Sibson DR, Holcombe C, Aachi V, Davies MP.
BMC Cancer. 2007 Jul 18;7:131.
Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Derin D, Eralp Y, Ozluk Y, Yavuz E, Guney N, Saip P, Igci A, Ozmen V, Kücücük S, Aslay I, Aydiner A, Topuz E.
Cancer Invest. 2008 Aug;26(7):671-9.
Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients.
Ludovini V, Sidoni A, Pistola L, Bellezza G, De Angelis V, Gori S, Mosconi AM, Bisagni G, Cherubini R, Bian AR, Rodinò C, Sabbatini R, Mazzocchi B, Bucciarelli E, Tonato M, Colozza M.
Breast Cancer Res Treat. 2003 Sep;81(2):159-68.
c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation.
Quaranta M, Daniele A, Coviello M, Savonarola A, Abbate I, Venneri MT, Paradiso A, Stea B, Zito A, Labriola A, Schittulli F.
Tumori. 2006 Jul-Aug;92(4):311-7.
GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value.
Voduc D, Cheang M, Nielsen T.
Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):365-73.
Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A, Kontogiannea M, Halwani F, Edwardes M, Meterissian S.
J Am Coll Surg. 2004 Jan;198(1):83-90.
Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma.
Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, Di GH, Liu G, Li FM, Ou ZL, Jie C, Shen ZZ, Shao ZM.
Breast Cancer Res Treat. 2004 Nov;88(1):75-85.
FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21.
Male breast cancer in the veterans affairs population: a comparative analysis.
Nahleh ZA, Srikantiah R, Safa M, Jazieh AR, Muhleman A, Komrokji R.
Cancer. 2007 Apr 15;109(8):1471-7.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on